cyprotex
the ADME Tox specialists
welcome to cyprotex

Investor News

January 23, 2009 - Trading Update

Cyprotex PLC (LSE: CRX), the drug discovery technology and information company, announces a trading update on its performance in the calendar year ending 31 December 2008.

Trading in the months of November and December 2008 was stronger than anticipated and as a result the Directors expect 2008 full year net profits (including significant adjustments for non-recurring costs) to be in excess of the current market expectations.

Cyprotex PLC
Dr Anthony Baxter, CEO
Tel: +44 (0)1625 505 100
ir@cyprotex.com
www.cyprotex.com

Nomura Code Securities Limited
Charles Walker, Corporate Finance
Tel: +44 (0)20 7776 1200
cew@nomuracode.com
www.nomuracode.com

Media Enquires
Pelham PR

Simon Miller
Tel: +44 (0)20 3178 4419
simon.miller@pelhampr.com
www.pelhampr.com

view all the latest news +
2013 archive +
2012 archive +
2011 archive +
2010 archive +
2009 archive +
2008 archive +
2007 archive +
2006 archive +
2005 archive +
2004 archive +
2003 archive +
2002 archive +
contact

Find out more about us.

Investor Relations
Anthony Baxter/Mark Warburton

Call on +44 1625 505100

contact
careerscontactlegalprivacy
This website was last updated
on 22nd April 2014
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.